Renalase-boosting treatment for acute pancreatitis
Development of a novel renalase agonist for the treatment of acute pancreatitis
A new medication that mimics the natural protein renalase to help people with acute pancreatitis by lowering inflammation, pain, and organ damage.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bessor Pharma, LLC NIH-funded |
| Lab location | 1 site (Framingham, United States) |
| Project ID | NIH-11185528 on NIH RePORTER |
What this research studies
This project is creating a medication that acts like renalase, a natural protein that can protect tissues and reduce inflammation. The company made a peptide called BP-1002 and an ELISA test to measure renalase levels, and animal studies show renalase falls during pancreatitis and giving RNLS or BP-1002 improves outcomes. The current work focuses on optimizing the compound, checking safety and dosing, and preparing the drug for possible human testing. If human trials proceed, they would likely target people early in an acute pancreatitis attack to see if the treatment reduces pain, organ failure, and hospital time.
Who could benefit from this research
Good fit: People with acute pancreatitis, especially those hospitalized early after symptom onset and at risk for severe disease, would be the most likely candidates for future trials.
Not a fit: Those with chronic pancreatitis, mild self-resolving episodes, or abdominal pain from other causes are unlikely to benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this approach could reduce the severity of attacks, shorten hospital stays, lower pain, and cut complications and deaths from acute pancreatitis.
How similar studies have performed: Preclinical animal studies and measurements in patients show promise for renalase approaches, but therapies like BP-1002 have not yet been tested in human clinical trials.
Where this research is happening
Framingham, United States
- Bessor Pharma, LLC — Framingham, United States (Active)
Researchers
- Principal investigator: Ohlstein, Eliot — Bessor Pharma, LLC
- Study coordinator: Ohlstein, Eliot
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.